Postoperative Opt-In Narcotic Treatment Study

NACompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

June 26, 2020

Primary Completion Date

January 30, 2021

Study Completion Date

January 30, 2021

Conditions
Postoperative PainNarcotic UseAnalgesiaEndocrine SurgeryOpioid UseOpioid Abuse
Interventions
BEHAVIORAL

POINT

Patients randomized to the POINT program will be given preoperative counseling on adverse effects of opioids and expectations will be set that most patients do not require opioids for pain control after endocrine surgery, they will receive the info in writing afterwards as well. These patients will also be shown a short instructional video reiterating the counseling provided in the preoperative clinic visit. Information in the video will pertain to the expected pain after surgery, the over-the-counter options for pain control, the risks and side effects of using opioids, and reassurances that opioids may be prescribed at any time after discharge if pain is unmanageable. After the video, the patient will be provided with paperwork, requiring patient consent/signature to receive opioids if they opt into narcotic treatment. They will not be provided with a narcotic prescription if consent is not explicitly provided.

Trial Locations (1)

90095

UCLA Medical Center, Los Angeles

All Listed Sponsors
lead

University of California, Los Angeles

OTHER

NCT04710069 - Postoperative Opt-In Narcotic Treatment Study | Biotech Hunter | Biotech Hunter